Cargando…
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression and treatment responses in genetically engineered mouse models of solid human cancers, but the potential of integrated FDG-PET/CT for assessing...
Autores principales: | Duncan, K, Rosean, T R, Tompkins, V S, Olivier, A, Sompallae, R, Zhan, F, Tricot, G, Acevedo, M R, Ponto, L L B, Walsh, S A, Tygrett, L T, Berger, A J, Waldschmidt, T, Morse, H C, Sunderland, J J, Janz, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880444/ https://www.ncbi.nlm.nih.gov/pubmed/24292417 http://dx.doi.org/10.1038/bcj.2013.61 |
Ejemplares similares
-
Transgenic mouse model of IgM(+) lymphoproliferative disease mimicking Waldenström macroglobulinemia
por: Tompkins, V S, et al.
Publicado: (2016) -
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018) -
KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice
por: Rosean, T R, et al.
Publicado: (2016) -
Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017) -
Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)